Formycon

𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐂𝐚𝐥𝐥 𝐨𝐧 𝐭𝐡𝐞 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝟐𝟎𝟐𝟓 𝐅𝐢𝐬𝐜𝐚𝐥 𝐘𝐞𝐚𝐫 To follow the conference live, please register via the following link: webcast-eqs.com/formycon-2025-… Access the replay at: formycon.com/en/investor-re…

The European Biotechnology Science & Industry Guide is more than just a “Who's Who” of European biotechnology. It also highlights current developments in innovation, deals and financing. With its biosimilar projects, Formycon is happy to be featured in the current edition.

𝐅𝐨𝐫𝐦𝐲𝐜𝐨𝐧 𝐬𝐞𝐜𝐮𝐫𝐞𝐬 𝐥𝐢𝐜𝐞𝐧𝐬𝐞 𝐝𝐚𝐭𝐞 𝐟𝐨𝐫 𝐅𝐘𝐁𝟐𝟎𝟑 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞 𝐚𝐧𝐝 𝐟𝐮𝐫𝐭𝐡𝐞𝐫 𝐭𝐞𝐫𝐫𝐢𝐭𝐨𝐫𝐢𝐞𝐬 Market launches by commercialization partners across Europe to start in May 2026 formycon.com/en/blog/press-…

🔬 Dahlia study demonstrates PK equivalence of FYB206 with the reference drug Keytruda® formycon.com/en/blog/press-…

We are happy to announce another milestone in our global commercialization journey for FYB206: formycon.com/en/blog/press-…

The FDA has approved Nufymco®, another interchangeable #ranibizumab #biosimilar in the U.S., underscoring Formycon’s pioneering position in high-quality biosimilar #development: formycon.com/en/blog/press-…

Zydus Lifesciences Limited to commercialize Formycon’s Keytruda biosimilar FYB206 in the US and Canada: formycon.com/en/blog/press-…

Formycon starts commercial partnering activities for #FYB206: MS Pharma will commercialize the Keytruda® biosimilar candidate in the #MENA region: formycon.com/en/blog/press-…

Immunological Dupilumab Biosimilar Candidate FYB208 as another growth driver in Formycon's portfolio formycon.com/en/blog/press-…

#WorldPsoriasisDay Psoriatic Disease and Comorbidities - Early Diagnosis and proper Treatment save Lives formycon.com/en/blog/2025/1…

Formycon sets a new standard: FYB201/Ranivisio®is the first ranibizumab biosimilar on the European market in a pre-filled syringe presentation For more information, please check our press release at: formycon.com/en/blog/press-…

Additional commercialization partnerships for FYB203 to open up further important regions of the world: formycon.com/en/blog/press-…

Preserving vision – Anti-VEGF therapies for severe retinopathies 👁️​ On World Sight Day, we we are turning our attention to retinopathies, in other words: diseases of the retina that can be responsible for severe visual impairment and even blindness: formycon.com/en/blog/2025/1…

Formycon and Klinge expand their European commercialization strategy for the Eylea® biosimilar FYB203 with Horus Pharma as additional commercialization partner formycon.com/en/blog/press-…

Dr. Andreas Seidl, Chief Scientific Officer (CSO) of Formycon AG, is Key Expert Speaker and Chairperson of today's first day of the 15th Biosimilars & Biologics Congress 2025 Europe in London.

Formycon publishes financial results of H1 2025 formycon.com/en/blog/press-…

𝐅𝐨𝐫𝐦𝐲𝐜𝐨𝐧 𝐢𝐧𝐯𝐢𝐭𝐞𝐬 𝐭𝐨 𝐜𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐜𝐚𝐥𝐥 𝐨𝐧 𝟐𝟎𝟐𝟓 𝐡𝐚𝐥𝐟-𝐲𝐞𝐚𝐫 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 You can join the presentation and Q&A on August 13, 2025, at 3:00 PM (CEST)live via the following link: webcast-eqs.com/formycon-2025-…

🚀 Even though we at Formycon have already celebrated many product launches, the #launch of Fymskina® in #Germany is something special: because Fymskina® is a Formycon brand. Formycon not only holds the marketing authorization but is also responsible for the entire supply chain.

Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206 formycon.com/en/blog/press-…

@BioUsawa becomes partner for the #commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan #Africa formycon.com/en/blog/press-…